FREDERICK, Md., Aug. 4, 2015 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of drug-free over-the-counter ActiPatch® Musculoskeletal Pain Therapy medical devices, announced today that its registry study of 44,000 users of its ActiPatch 7-day trial device has been published in the prominent peer reviewed medical journal Pain Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35. More than 5,000 chronic pain sufferers responded to the survey and submitted an assessment.
Chronic pain is a major unmet medical need that affects 20 to 40 % of the global population (more than diabetes, heart disease and cancer combined.) The majority of chronic pain causes, 80-85%, are musculoskeletal in nature. Despite using an average of 1.9 drugs for pain, 86% of the respondents reported that prior to using ActiPatch, they had pain levels of 8+ on a 11 point VAS scale- indicating severe unresolved pain. Pain was reduced an average of 57% for 65% of ActiPatch Therapy users who reported suffering from conditions such as osteoarthritis, rheumatoid arthritis, fibromyalgia, sports injuries, post-surgical pain, tendonitis, and neuropathy. There were no side effects reported.
A 3-month follow-up survey indicated 80% of ActiPatch users continued to purchase and use ActiPatch. The long-term effectiveness of ActiPatch therapy was confirmed by 93% of survey respondents reporting sustained pain relief, a distinct decrease in their medication use, and a significant improvement in their quality of life.
Dr. Deepak Kotak, Executive VP of BioElectronics, a Fellow of the Royal College of Anesthesiologists said, "Musculoskeletal pain is an increasing problem with few appropriate, safe, drug solutions. ActiPatch is a safe, affordable, self-treatment for chronic pain."
The details of previously completed and published clinical trials can be found at http://www.bielcorp.com/clinical-evidence/.
About BioElectronics Corporation
BioElectronics Corporation is a leader in Bioelectroceutical devices and the maker of an industry leading family of disposable, drug-free, anti-inflammatory devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; HealFast® Therapy for veterinary applications, Allay® Menstrual Pain Therapy and Smart Insole™ Heel Pain Therapy. Visit www.bielcorp.com for more information.
About the Pain Management Journal
Future Medicine Ltd, the publisher, has developed an innovative publishing portfolio to reflect the advances in post genomic medicine and to guide best clinical practice in modern medicine. The Future Medicine journal collection provides healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in the light of advances in molecular medicine and clinical practice.
SOURCE BioElectronics Corporation